Use of first or second trimester serum markers, or both, to predict preeclampsia

Pregnancy Hypertension

Volumn 4, Issue 4, 2014, Pages 271-278

  Lambert Messerlian, Geralyn ^a   Eklund, Elizabeth E ^a   Chien, Edward K ^b   Rosene Montella, Karen ^c   Neveux, Louis M ^a   Haddow, Hamish R M ^d   Palomaki, Glenn E ^a  

^a BROWN UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d Institute of Preventive Medicine and Medical Screening Unit 1   (United States)

Author keywords

Endoglin; Inhibin A; PAPP A; PlGF; Preeclampsia

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; FOLLISTATIN LIKE RELATED GENE PROTEIN; FOLLISTATIN RELATED PROTEIN; INHIBIN A; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PREECLAMPSIA; SECOND TRIMESTER PREGNANCY;

EID: 84916942595     PISSN: 22107789     EISSN: 22107797     Source Type: Journal    
DOI: 10.1016/j.preghy.2014.07.001     Document Type: Article

References (45)

1. A.P. MacKay, C.J. Berg, and H.K. Atrash Pregnancy-related mortality from preeclampsia and eclampsia Obstet Gynecol 97 2001 533 538
2. S. Roberge, K.H. Nicolaides, S. Demers, P. Villa, and E. Bujold Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis Ultrasound Obstet Gynecol 41 2013 491 499
3. T. Chaiworapongsa, R. Romero, A. Tarca, J.P. Kusanovic, P. Mittal, and S.K. Kim A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study J Matern Fetal Neonatal Med 22 2009 1122 1139
4. A. De Vivo, G. Baviera, D. Giordano, G. Todarello, F. Corrado, and R. D'Anna Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia Acta Obstet Gynecol Scand 87 2008 837 842
5. C.E. Kleinrouweler, M.M. Wiegerinck, C. Ris-Stalpers, P.M. Bossuyt, J.A. van der Post, and P. von Dadelszen Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis BJOG 119 2012 778 787
6. R.J. Levine, C. Lam, C. Qian, K.F. Yu, S.E. Maynard, and B.P. Sachs Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 2006 992 1005
7. K.A. Wathen, E. Tuutti, U.H. Stenman, H. Alfthan, E. Halmesmaki, and P. Finne Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation J Clin Endocrinol Metab 91 2006 180 184
8. J.H. Kang, A. Farina, J.H. Park, S.H. Kim, J.Y. Kim, and N. Rizzo Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity Prenat Diagn 28 2008 704 709
9. G.M. Lambert-Messerlian, H.M. Silver, F. Petraglia, S. Luisi, I. Pezzani, and W.M. Maybruck Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin A as predictors of preeclampsia in the third trimester of pregnancy J Soc Gynecol Investig 7 2000 170 174
10. N.J. Wald, J.K. Morris, J. Ibison, T. Wu, and L.M. George Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers Prenat Diagn 26 2006 559 564
11. F. D'Antonio, C. Rijo, B. Thilaganathan, R. Akolekar, A. Khalil, and A. Papageourgiou Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications Prenat Diagn 33 2013 839 847
12. K. Pryor-Koishi, H. Nishizawa, T. Kato, H. Kogo, T. Murakami, and K. Tsuchida Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia BJOG 114 2007 1128 1137
13. ACOG Committee on Obstetric Practice ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. American College of Obstetricians and Gynecologists Int J Gynaecol Obstet 2002 77 January 2002 67 75
14. G.E. Palomaki, D.E. Wright, A.M. Summers, L.M. Neveux, C. Meier, and A. O'Donnell Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study Prenat Diagn 26 2006 730 739
15. A. Jeyabalan Epidemiology of preeclampsia: impact of obesity Nutr Rev 71 Suppl. 1 2013 S18 S25
16. N.J. Wald, J.P. Bestwick, and J.K. Morris Cross-trimester marker ratios in prenatal screening for Down syndrome Prenat Diagn 26 2006 514 523
17. D. Wright, I. Bradbury, F. Malone, M. D'Alton, A. Summers, and T. Huang Cross-trimester repeated measures testing for Down's syndrome screening: an assessment Health Technol Assess 14 2010 1 80
18. F. Audibert, I. Boucoiran, N. An, N. Aleksandrov, E. Delvin, and E. Bujold Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women Am J Obstet Gynecol 203 383 2010 e1 e8
19. N.A. Bersinger, and R.A. Odegard Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies Acta Obstet Gynecol Scand 83 2004 37 45
20. J.P. Bestwick, L.M. George, T. Wu, J.K. Morris, and N.J. Wald The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia J Med Screen 19 2012 51 54
21. I. Boucoiran, E. Suarthana, E. Rey, E. Delvin, W.B. Fraser, and F. Audibert Repeated measures of placental growth factor, placental protein 13, and a disintegrin and metalloprotease 12 at first and second trimesters for preeclampsia screening Am J Perinatol 30 2013 681 688
22. G.M. Lambert-Messerlian, G.E. Palomaki, L.M. Neveux, E. Chien, A. Friedman, and K. Rosene-Montella Early onset preeclampsia and second trimester serum markers Prenat Diagn 29 2009 1109 1117
23. A.O. Odibo, Y. Zhong, K.R. Goetzinger, L. Odibo, J.L. Bick, and C.R. Bower First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia Placenta 32 2011 598 602
24. L.C. Poon, A. Syngelaki, R. Akolekar, J. Lai, and K.H. Nicolaides Combined screening for preeclampsia and small for gestational age at 11-13 weeks Fetal Diagn Ther 33 2013 16 27
25. N.J. Wald, J.P. Bestwick, L.M. George, T. Wu, and J.K. Morris Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers J Med Screen 19 2012 60 67
26. R. Akolekar, A. Syngelaki, R. Sarquis, M. Zvanca, and K.H. Nicolaides Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks Prenat Diagn 31 2011 66 74
27. S. Kuc, E.J. Wortelboer, B.B. van Rijn, A. Franx, G.H. Visser, and P.C. Schielen Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review Obstet Gynecol Surv 66 2011 225 239
28. K. Spencer, N.J. Cowans, and K.H. Nicolaides Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia Ultrasound Obstet Gynecol 32 2008 622 626
29. J. Yu, C.Z. Shixia, Y. Wu, and T. Duan Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia Ultrasound Obstet Gynecol 37 2011 528 533
30. P.H. Ree, W.B. Hahn, S.W. Chang, S.H. Jung, J.H. Kang, and D.H. Cha Early detection of preeclampsia using inhibin A and other second-trimester serum markers Fetal Diagn Ther 29 2011 280 286
31. M.U. Baumann, N.A. Bersinger, M.G. Mohaupt, L. Raio, S. Gerber, and D.V. Surbek First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia Am J Obstet Gynecol 199 266 2008 e1 e6
32. M. Jacobs, N. Nassar, C.L. Roberts, R. Hadfield, J.M. Morris, and A.W. Ashton Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review Reprod Biol Endocrinol 9 2011 77
33. A. Goel, and S. Rana Angiogenic factors in preeclampsia: potential for diagnosis and treatment Curr Opin Nephrol Hypertens 22 2013 643 650
34. O. Erez, R. Romero, J. Espinoza, W. Fu, D. Todem, and J.P. Kusanovic The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age J Matern Fetal Neonatal Med 21 2008 279 287
35. S.K. Ghosh, S. Raheja, A. Tuli, C. Raghunandan, and S. Agarwal Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy? Arch Gynecol Obstet 287 2013 865 873
36. T.F. McElrath, K.H. Lim, E. Pare, J. Rich-Edwards, D. Pucci, and R. Troisi Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy Am J Obstet Gynecol 207 407 2012 e1 e7
37. T.A. Moore Simas, S.L. Crawford, S. Bathgate, J. Yan, L. Robidoux, and M. Moore Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women J Matern Fetal Neonatal Med. 27 2013 1038 1048
38. L. Myatt, R.G. Clifton, J.M. Roberts, C.Y. Spong, R.J. Wapner, and J.M. Thorp Jr Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 120 2013 1183 1191
39. M. Noori, A.E. Donald, A. Angelakopoulou, A.D. Hingorani, and D.J. Williams Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension Circulation 122 2010 478 487
40. R. Romero, J.K. Nien, J. Espinoza, D. Todem, W. Fu, and H. Chung A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate J Matern Fetal Neonatal Med 21 2008 9 23
41. American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. 2013 [cited 2014 January 14]. Available from: < http://www.acog.org/~/media/Task%20Force%20and%20Work%20Group%20Reports/HypertensioninPregnancy.pdf >.
42. J. Zhang, G. Lambert-Messerlian, G.E. Palomaki, and J.A. Canick Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters Prenat Diagn 31 2011 583 588
43. A.K. Wikstrom, O. Stephansson, and S. Cnattingius Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff Hypertension 55 2010 1254 1259
44. WHO Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia. Geneva: World Heatlh Organization; 2011. Available from: < http://www.ncbi.nlm.nih.gov/books/NBK140561/ >.
45. S.E. Maynard, and S.A. Karumanchi Angiogenic factors and preeclampsia Semin Nephrol 31 2011 33 46